<img src="https://ml.globenewswire.com/Resource/Download/36fb7b98-27d7-46cb-b989-fa31626657b8?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Nanobiotix logo.jpg" alt="Nanobiotix S.A."/>In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, June 05, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website: <a href="https://www.globenewswire.com/Tracker?data=NWR67_0vEpvqXynOQE8fJTnugozHZEbuASmLfJ9lLCkvmw3dX4XawY9aHKxo71R3aj5Gz9ZOqChP2vrjsaqN4hUpUuyPVA346KwhwAO57fw=" rel="nofollow" target="_blank" title="www.nanobiotix.com">www.nanobiotix.com</a> <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td rowspan="2" style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Date</td><td rowspan="2" style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Number of Shares Outstanding</td><td colspan="2" style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Total number of voting rights</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Total voting rights, theoretical1</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Total voting rights, exercisable2</td></tr><tr><td style="max-width:25%; width:25%; min-width:25%;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">May 31, 2026</td><td style="max-width:25%; width:25%; min-width:25%;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">50,807,903</td><td style="max-width:25%; width:25%; min-width:25%;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">54,304,858</td><td style="max-width:25%; width:25%; min-width:25%;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">54,282,740</td></tr></table>   About NANOBIOTIX Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has a subsidiary in Cambridge, Massachusetts (United States). Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. For more information about Nanobiotix, visit us at <a href="https://www.globenewswire.com/Tracker?data=NWR67_0vEpvqXynOQE8fJVLG05F-i8TQyUWEgw011mxmwWrdIDWjzXjqT3TbGQ0-ZbwN5hdh5V0DcJwGDn61P9YhjKQJDTGxHL4ddob65ME=" rel="nofollow" target="_blank" title="www.nanobiotix.com">www.nanobiotix.com</a> or follow us on <a href="https://www.globenewswire.com/Tracker?data=AqrEKChqRVj70L9sT0p1IS3d_8z6b_h0H8M41_1S_79e76H6YJnUmzP-qEjs_GzNJ75BamfXrNSDRS6vsuLNrSZfyJdrv-EYyqy4bbuwD44=" rel="nofollow" target="_blank" title="LinkedIn">LinkedIn</a> and <a href="https://www.globenewswire.com/Tracker?data=9w45MgLtby_AyBomwNeXnN6gkmY8KcZaTR15Hx3E2GZpn3p1IASHhU9zPhperskCzYcV8VBCtPmb_hpOQkzG0iJnQsVBN4wGKBLdGnN6eb0=" rel="nofollow" target="_blank" title="Twitter">Twitter</a>. _______________________________ 1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended. 2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed. Contacts <table style="border-top: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Nanobiotix</td></tr><tr><td style="max-width:50%; width:50%; min-width:50%;;border-bottom: solid black 1pt ; vertical-align: middle ; ">Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 <a href="mailto:contact@nanobiotix.com" rel="nofollow" target="_blank" title="contact@nanobiotix.com">contact@nanobiotix.com</a></td><td style="max-width:50%; width:50%; min-width:50%;;border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; "> Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) <a href="mailto:investors@nanobiotix.com" rel="nofollow" target="_blank" title="investors@nanobiotix.com">investors@nanobiotix.com</a> </td></tr><tr><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Media Relations</td></tr><tr><td style="vertical-align: middle ; "> France – HARDY Caroline Hardy +33 06 70 33 49 50 <a href="mailto:carolinehardy@outlook.fr" rel="nofollow" target="_blank" title="">carolinehardy@outlook.fr</a> </td><td style="border-top: solid black 1pt ; vertical-align: middle ; ">Global – uncapped Becky Lauer +1 (646) 286-0057 <a href="mailto:uncappednanobiotix@uncappedcommunications.com" rel="nofollow" target="_blank" title="uncappednanobiotix@uncappedcommunications.com">uncappednanobiotix@uncappedcommunications.com</a></td></tr></table> Attachment <ul id="gnw_attachments_section-items"><li> <a href="https://www.globenewswire.com/Tracker?data=Cvze33_gucEuK-HAHjfUdeAmxdZV28eC4NdHCcfeyHWnJYihBJDznVb33CWIcDxUd3dT0dDrism7BvWsIpXWqR-GGJeSH6G5Xs1M5dVRtdPk567m-TO_9RCb6fkxzJF3IJO930xBkU6h5Ozh-3EF7cAdTZaZLCLpPd8QChBSboSTr-cNoTZWIioQFJkdsf_Lc1Cm1oc1KndqJkkRE2WeTvIJKC2mb5MRfJ7faPfr4_U=" rel="nofollow" target="_blank" title="2026-06-05 -- NBTX -- Voting Rights &amp; Shares Capital -- FINAL">2026-06-05 -- NBTX -- Voting Rights &amp; Shares Capital -- FINAL</a> </li></ul> <img alt="" src='https://ml.globenewswire.com/media/YzIxMzhiM2EtMjVmMi00YzI2LTg4ZjAtMjk0MmFjODZjNWRhLTEwMTExNjItMjAyNi0wNi0wNS1lbg==/tiny/Nanobiotix-S-A-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Voting Rights and Shares Capital of the Company

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn